Latest news with #MikeDruhan
Business Wire
21-05-2025
- Business
- Business Wire
MedX Health, Vitamed Biomedical, and Medispa Partner to Expand Teledermatology Services Across Italy
MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. ('MedX' or the 'Company') (TSXV: MDX), a global leader in teledermatology, is pleased to announce a strategic collaboration in the Italian healthcare market between Vitamed Biomedical, a MedX commercial partner in Italy, and Medispa, a leading Italian healthcare company delivering innovative digital solutions for prevention, wellness, and healthcare. This new partnership will facilitate the deployment of MedX's proprietary SIAscope on DermSecure® platform across Medispa's extensive network of pharmacies, medical centers, and wellness facilities, increasing patient access to advanced skin screening and preventive care. 'We are pleased to support our partners Vitamed Biomedical and Medispa in bringing our SIAscope on DermSecure® system to a broader patient base in Italy,' said Mike Druhan, President of Dermatological Services at MedX Health Corp. 'This collaboration is an important milestone in our international expansion strategy and underscores our commitment to enabling early detection of melanoma by a dermatologist through accessible, non-invasive teledermatology.' The SIAscope on DermSecure® system enables rapid, non-invasive imaging of suspicious skin lesions, which are securely transmitted for dermatologist review often within 72 hours dramatically accelerating diagnosis while reducing unnecessary referrals and wait times. The solution has been cleared for clinical use across multiple jurisdictions, including the EU, Canada, the U.S., Australia, and the UK. 'This collaboration with Medispa strengthens our mission to expand the reach of teledermatology in Italy,' said Giuseppe Verderame, CEO of Vitamed Biomedical. 'By integrating MedX's platform into high-traffic and trusted community hubs like pharmacies and wellness centers, we are improving accessibility and empowering individuals with better tools for early skin cancer detection.' Andrea Prina, CEO of Medispa, added: 'This partnership perfectly aligns with Medispa's vision of innovating healthcare delivery through digital technology. By offering MedX's solution through our network, we're providing citizens with fast, reliable access to dermatological screening and reinforcing our commitment to prevention-first health services.' Italy represents a key European growth market for MedX Health, where demand for accessible, specialist-level dermatological screening continues to grow particularly in light of increased awareness of skin cancer risks associated with aging populations and sun exposure. About Vitamed Biomedical Vitamed Biomedical is a provider of advanced medical technologies and a commercial partner of MedX in Italy. The company focuses on distributing innovative healthcare solutions that support early diagnosis and patient-centered care across Italy's public and private healthcare sectors. About Medispa Medispa is an Italian company specializing in digital innovation for prevention and wellness services. With a strong presence in pharmacies, medical clinics, and wellness centers, Medispa is dedicated to delivering integrated, forward-thinking health services for the modern consumer. About MedX Health Corp. MedX Health Corp., headquartered in Ontario, Canada, is a leading developer of non-invasive skin analysis and teledermatology solutions. Its SIAscopy® technology, integrated into the DermSecure® platform, enables pain-free imaging of skin lesions for rapid remote dermatologist assessment. MedX products are cleared for use in Canada, the United States, Europe, Australia, and several other markets. Visit: Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This media release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. These statements involve risks and uncertainties.
Yahoo
15-05-2025
- Business
- Yahoo
MedX Health and Health Partners Sign Commercial Agreement Following Successful UK Pilot
MISSISSAUGA, Ontario, May 15, 2025--(BUSINESS WIRE)--MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), the global leader in teledermatology solutions, is pleased to announce the signing of a commercial contract with Health Partners Group Ltd ("HPG" or "Health Partners Group"), the United Kingdom's largest occupational health services provider. This agreement follows the successful completion of a pilot project across two of HPG's clients, utilizing MedX's DermSecure® skin cancer screening platform. Following the pilot's success (11% of 300 employees from two of HPG's clients had moles requiring in-clinic dermatological follow-up), MedX's DermSecure® skin cancer screening platform will be rolled out to Health Partners' clients across the UK and the Republic of Ireland, representing a major milestone in MedX's global commercialization strategy. "We are thrilled to deepen our relationship with Health Partners through this commercial agreement," said Mike Druhan, President of Dermatological Services at MedX. "This rollout means potentially thousands of at-risk individuals, particularly outdoor and industrial workers, will gain access to dermatologist-level skin assessments, directly at their workplaces. Health Partners Group is offering MedX services as a fast-track to a Dermatologist, which is a powerful step forward in the early detection and prevention of skin cancer in the workplace." With three million client employees served and 650+ corporate, government, and insurance clients, Health Partners Group is now poised to offer scalable, remote skin cancer screening as a standard part of their client employee health services. "The pilot validated the accuracy, speed, and accessibility of MedX's technology," said Andrew Noble, CEO of Health Partners Group. "Preventive care is essential to workplace health. Health Partners Group is extending its preventative care and chronic care services to include Skin Cancer screening. This is a complementary partnership that enables Health Partners to integrate world-class dermatological assessments into our existing services, speeding up diagnosis to under 3 days from the current NHS wait time of between 5-9 months and helping safeguard the health of the UK's workforce." Skin cancer is among the most common forms of cancer in the UK, with over 220,000 cases diagnosed annually. According to the UK Cancer Alliance, outdoor workers face a 60% higher risk of developing skin cancer due to prolonged sun exposure. Early detection remains critical, with survival rates dropping sharply between early and late-stage diagnoses. The MedX platform allows rapid, non-invasive imaging of skin lesions, which are securely transmitted to dermatologists for assessment within a period of 72 hours or less. The rollout represents a pivotal advancement in accessible, preventative care, especially at a time when healthcare systems face growing demand and staffing pressures. About Health Partners Group Partners Group is the UK's leading occupational health and primary care provider, supporting corporate, government, insurance, and individual clients across the UK and Republic of Ireland. With over 1,300 staff and a robust technology platform, Health Partners Group delivers personalized and scalable health solutions. Visit: About MedX Health Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy® technology, integrated into the DermSecure® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. Visit: Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. View source version on Contacts Investor & Media Contact: MedX Health Druhan, President of Dermatological Services(+1)
Associated Press
15-05-2025
- Business
- Associated Press
MedX Health and Health Partners Sign Commercial Agreement Following Successful UK Pilot
MISSISSAUGA, Ontario--(BUSINESS WIRE)--May 15, 2025-- MedX Health Corp. (' MedX ' or the ' Company ') (TSXV: MDX ), the global leader in teledermatology solutions, is pleased to announce the signing of a commercial contract with Health Partners Group Ltd (' HPG ' or ' Health Partners Group '), the United Kingdom's largest occupational health services provider. This agreement follows the successful completion of a pilot project across two of HPG's clients, utilizing MedX's DermSecure® skin cancer screening platform. Following the pilot's success (11% of 300 employees from two of HPG's clients had moles requiring in-clinic dermatological follow-up), MedX's DermSecure® skin cancer screening platform will be rolled out to Health Partners' clients across the UK and the Republic of Ireland, representing a major milestone in MedX's global commercialization strategy. 'We are thrilled to deepen our relationship with Health Partners through this commercial agreement,' said Mike Druhan, President of Dermatological Services at MedX. 'This rollout means potentially thousands of at-risk individuals, particularly outdoor and industrial workers, will gain access to dermatologist-level skin assessments, directly at their workplaces. Health Partners Group is offering MedX services as a fast-track to a Dermatologist, which is a powerful step forward in the early detection and prevention of skin cancer in the workplace.' With three million client employees served and 650+ corporate, government, and insurance clients, Health Partners Group is now poised to offer scalable, remote skin cancer screening as a standard part of their client employee health services. 'The pilot validated the accuracy, speed, and accessibility of MedX's technology,' said Andrew Noble, CEO of Health Partners Group. 'Preventive care is essential to workplace health. Health Partners Group is extending its preventative care and chronic care services to include Skin Cancer screening. This is a complementary partnership that enables Health Partners to integrate world-class dermatological assessments into our existing services, speeding up diagnosis to under 3 days from the current NHS wait time of between 5-9 months and helping safeguard the health of the UK's workforce.' Skin cancer is among the most common forms of cancer in the UK, with over 220,000 cases diagnosed annually. According to the UK Cancer Alliance, outdoor workers face a 60% higher risk of developing skin cancer due to prolonged sun exposure. Early detection remains critical, with survival rates dropping sharply between early and late-stage diagnoses. The MedX platform allows rapid, non-invasive imaging of skin lesions, which are securely transmitted to dermatologists for assessment within a period of 72 hours or less. The rollout represents a pivotal advancement in accessible, preventative care, especially at a time when healthcare systems face growing demand and staffing pressures. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. View source version on CONTACT: Investor & Media Contact: MedX Health Corp. Mike Druhan, President of Dermatological Services (+1) 905-599-7852 [email protected] KEYWORD: EUROPE UNITED KINGDOM NORTH AMERICA CANADA INDUSTRY KEYWORD: HEALTH TECHNOLOGY HEALTH TELEMEDICINE/VIRTUAL MEDICINE MEDICAL DEVICES SOURCE: MedX Health Corp. Copyright Business Wire 2025. PUB: 05/15/2025 09:40 AM/DISC: 05/15/2025 09:39 AM
National Post
15-05-2025
- Health
- National Post
MedX Health and Health Partners Sign Commercial Agreement Following Successful UK Pilot
Article content MISSISSAUGA, Ontario — MedX Health Corp. (' MedX ' or the ' Company ') (TSXV: MDX), the global leader in teledermatology solutions, is pleased to announce the signing of a commercial contract with Health Partners Group Ltd (' HPG ' or ' Health Partners Group '), the United Kingdom's largest occupational health services provider. This agreement follows the successful completion of a pilot project across two of HPG's clients, utilizing MedX's DermSecure® skin cancer screening platform. Article content Article content Following the pilot's success (11% of 300 employees from two of HPG's clients had moles requiring in-clinic dermatological follow-up), MedX's DermSecure® skin cancer screening platform will be rolled out to Health Partners' clients across the UK and the Republic of Ireland, representing a major milestone in MedX's global commercialization strategy. Article content 'We are thrilled to deepen our relationship with Health Partners through this commercial agreement,' said Mike Druhan, President of Dermatological Services at MedX. 'This rollout means potentially thousands of at-risk individuals, particularly outdoor and industrial workers, will gain access to dermatologist-level skin assessments, directly at their workplaces. Health Partners Group is offering MedX services as a fast-track to a Dermatologist, which is a powerful step forward in the early detection and prevention of skin cancer in the workplace.' Article content With three million client employees served and 650+ corporate, government, and insurance clients, Health Partners Group is now poised to offer scalable, remote skin cancer screening as a standard part of their client employee health services. Article content 'The pilot validated the accuracy, speed, and accessibility of MedX's technology,' said Andrew Noble, CEO of Health Partners Group. 'Preventive care is essential to workplace health. Health Partners Group is extending its preventative care and chronic care services to include Skin Cancer screening. This is a complementary partnership that enables Health Partners to integrate world-class dermatological assessments into our existing services, speeding up diagnosis to under 3 days from the current NHS wait time of between 5-9 months and helping safeguard the health of the UK's workforce.' Article content Skin cancer is among the most common forms of cancer in the UK, with over 220,000 cases diagnosed annually. According to the UK Cancer Alliance, outdoor workers face a 60% higher risk of developing skin cancer due to prolonged sun exposure. Early detection remains critical, with survival rates dropping sharply between early and late-stage diagnoses. Article content The MedX platform allows rapid, non-invasive imaging of skin lesions, which are securely transmitted to dermatologists for assessment within a period of 72 hours or less. The rollout represents a pivotal advancement in accessible, preventative care, especially at a time when healthcare systems face growing demand and staffing pressures. Article content About Health Partners Group Ltd. Health Partners Group is the UK's leading occupational health and primary care provider, supporting corporate, government, insurance, and individual clients across the UK and Republic of Ireland. With over 1,300 staff and a robust technology platform, Health Partners Group delivers personalized and scalable health solutions. Visit: Article content About MedX Health Corp. MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy® technology, integrated into the DermSecure® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. Visit: Article content Article content Article content Article content Article content Contacts Article content Article content Article content
Business Wire
15-05-2025
- Business
- Business Wire
MedX Health and Health Partners Sign Commercial Agreement Following Successful UK Pilot
MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. ('MedX' or the 'Company') (TSXV: MDX), the global leader in teledermatology solutions, is pleased to announce the signing of a commercial contract with Health Partners Group Ltd ('HPG' or 'Health Partners Group'), the United Kingdom's largest occupational health services provider. This agreement follows the successful completion of a pilot project across two of HPG's clients, utilizing MedX's DermSecure® skin cancer screening platform. Following the pilot's success (11% of 300 employees from two of HPG's clients had moles requiring in-clinic dermatological follow-up), MedX's DermSecure® skin cancer screening platform will be rolled out to Health Partners' clients across the UK and the Republic of Ireland, representing a major milestone in MedX's global commercialization strategy. 'We are thrilled to deepen our relationship with Health Partners through this commercial agreement,' said Mike Druhan, President of Dermatological Services at MedX. 'This rollout means potentially thousands of at-risk individuals, particularly outdoor and industrial workers, will gain access to dermatologist-level skin assessments, directly at their workplaces. Health Partners Group is offering MedX services as a fast-track to a Dermatologist, which is a powerful step forward in the early detection and prevention of skin cancer in the workplace.' With three million client employees served and 650+ corporate, government, and insurance clients, Health Partners Group is now poised to offer scalable, remote skin cancer screening as a standard part of their client employee health services. 'The pilot validated the accuracy, speed, and accessibility of MedX's technology,' said Andrew Noble, CEO of Health Partners Group. 'Preventive care is essential to workplace health. Health Partners Group is extending its preventative care and chronic care services to include Skin Cancer screening. This is a complementary partnership that enables Health Partners to integrate world-class dermatological assessments into our existing services, speeding up diagnosis to under 3 days from the current NHS wait time of between 5-9 months and helping safeguard the health of the UK's workforce.' Skin cancer is among the most common forms of cancer in the UK, with over 220,000 cases diagnosed annually. According to the UK Cancer Alliance, outdoor workers face a 60% higher risk of developing skin cancer due to prolonged sun exposure. Early detection remains critical, with survival rates dropping sharply between early and late-stage diagnoses. The MedX platform allows rapid, non-invasive imaging of skin lesions, which are securely transmitted to dermatologists for assessment within a period of 72 hours or less. The rollout represents a pivotal advancement in accessible, preventative care, especially at a time when healthcare systems face growing demand and staffing pressures. About Health Partners Group Ltd. Health Partners Group is the UK's leading occupational health and primary care provider, supporting corporate, government, insurance, and individual clients across the UK and Republic of Ireland. With over 1,300 staff and a robust technology platform, Health Partners Group delivers personalized and scalable health solutions. Visit: About MedX Health Corp. MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy® technology, integrated into the DermSecure® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. Visit: Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
